173 related articles for article (PubMed ID: 23977084)
1. Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T cell response in mice.
Chapman R; Stutz H; Jacobs W; Shephard E; Williamson AL
PLoS One; 2013; 8(8):e71601. PubMed ID: 23977084
[TBL] [Abstract][Full Text] [Related]
2. Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.
Chapman R; Shephard E; Stutz H; Douglass N; Sambandamurthy V; Garcia I; Ryffel B; Jacobs W; Williamson AL
PLoS One; 2012; 7(3):e32769. PubMed ID: 22479338
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice.
Jongwe TI; Chapman R; Douglass N; Chetty S; Chege G; Williamson AL
PLoS One; 2016; 11(7):e0159141. PubMed ID: 27427967
[TBL] [Abstract][Full Text] [Related]
4. Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.
Chege GK; Burgers WA; Stutz H; Meyers AE; Chapman R; Kiravu A; Bunjun R; Shephard EG; Jacobs WR; Rybicki EP; Williamson AL
J Virol; 2013 May; 87(9):5151-60. PubMed ID: 23449790
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites.
Yu JS; Peacock JW; Jacobs WR; Frothingham R; Letvin NL; Liao HX; Haynes BF
Clin Vaccine Immunol; 2007 Jul; 14(7):886-93. PubMed ID: 17507541
[TBL] [Abstract][Full Text] [Related]
6. Prime-boost immunization of codon optimized HIV-1 CRF01_AE Gag in BCG with recombinant vaccinia virus elicits MHC class I and II immune responses in mice.
Promkhatkaew D; Pinyosukhee N; Thongdeejaroen W; Teeka J; Wutthinantiwong P; Leangaramgul P; Sawanpanyalert P; Warachit P
Immunol Invest; 2009; 38(8):762-79. PubMed ID: 19860587
[TBL] [Abstract][Full Text] [Related]
7. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
[TBL] [Abstract][Full Text] [Related]
8. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.
Promkhatkaew D; Matsuo K; Pinyosukhee N; Thongdeejaroen W; Leang-Aramgul P; Sawanpanyalert P; Warachit P
Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):273-81. PubMed ID: 19323012
[TBL] [Abstract][Full Text] [Related]
9. Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.
Kim BJ; Kim BR; Kook YH; Kim BJ
Front Immunol; 2018; 9():643. PubMed ID: 29636755
[TBL] [Abstract][Full Text] [Related]
10. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
[TBL] [Abstract][Full Text] [Related]
11. The use of directed evolution to create a stable and immunogenic recombinant BCG expressing a modified HIV-1 Gag antigen.
Chapman R; Bourn WR; Shephard E; Stutz H; Douglass N; Mgwebi T; Meyers A; Chin'ombe N; Williamson AL
PLoS One; 2014; 9(7):e103314. PubMed ID: 25061753
[TBL] [Abstract][Full Text] [Related]
12. Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses.
Cayabyab MJ; Korioth-Schmitz B; Sun Y; Carville A; Balachandran H; Miura A; Carlson KR; Buzby AP; Haynes BF; Jacobs WR; Letvin NL
J Virol; 2009 Jun; 83(11):5505-13. PubMed ID: 19297477
[TBL] [Abstract][Full Text] [Related]
13. A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV).
Shen YJ; Shephard E; Douglass N; Johnston N; Adams C; Williamson C; Williamson AL
Virol J; 2011 May; 8():265. PubMed ID: 21624130
[TBL] [Abstract][Full Text] [Related]
14. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors.
Hopkins R; Bridgeman A; Bourne C; Mbewe-Mvula A; Sadoff JC; Both GW; Joseph J; Fulkerson J; Hanke T
Eur J Immunol; 2011 Dec; 41(12):3542-52. PubMed ID: 21932450
[TBL] [Abstract][Full Text] [Related]
15. A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons.
Chege GK; Thomas R; Shephard EG; Meyers A; Bourn W; Williamson C; Maclean J; Gray CM; Rybicki EP; Williamson AL
Vaccine; 2009 Jul; 27(35):4857-66. PubMed ID: 19520196
[TBL] [Abstract][Full Text] [Related]
16. Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.
Gómez CE; Perdiguero B; Jiménez V; Filali-Mouhim A; Ghneim K; Haddad EK; Quakkelaar ED; Delaloye J; Harari A; Roger T; Duhen T; Sékaly RP; Melief CJ; Calandra T; Sallusto F; Lanzavecchia A; Wagner R; Pantaleo G; Esteban M
PLoS One; 2012; 7(4):e35485. PubMed ID: 22536391
[TBL] [Abstract][Full Text] [Related]
17. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandström E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
J Virol; 2017 Sep; 91(18):. PubMed ID: 28701395
[TBL] [Abstract][Full Text] [Related]
18. Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.
Ratto-Kim S; Currier JR; Cox JH; Excler JL; Valencia-Micolta A; Thelian D; Lo V; Sayeed E; Polonis VR; Earl PL; Moss B; Robb ML; Michael NL; Kim JH; Marovich MA
PLoS One; 2012; 7(9):e45840. PubMed ID: 23049876
[TBL] [Abstract][Full Text] [Related]
19. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
20. Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C.
Burgers WA; Shephard E; Monroe JE; Greenhalgh T; Binder A; Hurter E; Van Harmelen JH; Williamson C; Williamson AL
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):195-206. PubMed ID: 18240957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
